web analytics

World first in UCC research

A UCC professor has shown in a trial, the first of its kind in the world,UCC that low dose insulin-like growth factor, injected into the heart to repair damage to the muscle, improves remodelling for heart attack patients.

Professor Noel Caplice, Chair of Cardiovascular Sciences at UCC, and his cardiologist colleagues at Cork University Hospital successfully tested the growth factor in the clinical trial (RESUS-AMI), funded by a €1 million grant under the joint HRB-SFI Translational Research Award programme, of 47 patients who had experienced large attacks.

Around 20% of people who suffer heart attacks have severe ongoing difficulties because of lasting damage to heart muscle even after the best current therapies, often resulting in patients developing long-term heart failure, associated with increased morbidity and mortality.

Patients received two different low dose preparations of insulin-like growth factor or placebo in a randomised double blinded clinical trial, with results showing those who received the higher dose had improved remodelling of their heart muscle in the two-month follow-up after their heart attack, which correlated with other measures of improved heart performance.

Click here to read full article …

2017-05-09T08:52:36+01:00 Categories: Medical, Research|Tags: |